CTKB Stock Analysis: Buy, Sell, or Hold?
CTKB - Cytek Biosciences, Inc. Common Stock
$4.81
0.15 (3.22%)
▲
5d:
+2.56%
30d:
+5.48%
90d:
+21.46%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When CTKB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CTKB shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CTKB shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CTKB is currently trading at $4.81, which is considered extended relative to its 30-day fair value range of $4.33 to $4.74. From a valuation perspective, the stock is trading at a premium (Forward PE: 68.7) compared to its historical average (54.3). At these levels, the market is pricing in 8.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CTKB is showing sideways momentum. The price is approaching resistance at $4.93. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: CTKB scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.56 (+15.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CTKB is showing sideways momentum. The price is approaching resistance at $4.93. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: CTKB scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.56 (+15.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.33 -
$4.74
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
30.0%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (13/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.2%)
- BULLISH: Trading below Wall St target ($5.56)
- NEUTRAL: Trading at premium valuation - market expects 8.1% growth which is achievable
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.33 -
$4.74
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.16
Resistance Level
$4.94
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
68.71
Wall Street Target
$5.56
(+15.6%)
Revenue Growth (YoY)
5.6%
Earnings Growth (YoY)
73.5%
Profit Margin
-39.0%
Valuation Premium vs History
+8.1% premium
PE vs Historical
68.7 vs 54.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.1%
(market-implied from PE analysis)
1-Year Target
$5.20
(+8%)
2-Year Target
$5.62
(+17%)
3-Year Target
$6.08
(+26%)
3-Yr Target (if PE normalizes)
(PE: 69→54)
PE COMPRESSION
$4.80
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: August 22, 2026 5:38 PM ET
Data refreshes hourly during market hours. Next update: 6:38 PM
Data refreshes hourly during market hours. Next update: 6:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTKB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 48 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$119 | 37 SELL |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 49 HOLD |
